Skip to content
Back to News Hub
Medical Health Aged Care

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Zenas BioPharma 2 mins read

WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com


Primary Logo

More from this category

  • Medical Health Aged Care
  • 07/11/2024
  • 23:11
Tilray Brands, Inc.

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

SYDNEY, Australia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, is pleased to announce the final results of a new scientific study their team has supported titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)."This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing…

  • Medical Health Aged Care
  • 07/11/2024
  • 13:47
Royal Australian College of GPs

RACGP applauds LNP for abolishing payroll tax on GPs

The Royal Australian College of General Practitioners (RACGP) has praised the Crisafulli Government for instructing Treasury to abolish payroll tax on GPs, making general practice care more affordable for all Queenslanders. RACGP Queensland Chair Dr Cath Hester applauded the new government for acting on the College’s calls. “As Australia’s peak body for general practitioners and GP training, the RACGP has long advocated for this tax to be abolished, and I’m thrilled the Crisafulli Government has instructed Treasury to do so. “This will help to ensure essential GP care stays affordable for Queenslanders, and practices can remain viable and keep their…

  • Medical Health Aged Care
  • 07/11/2024
  • 11:34
Primary Care Business Council

Caution needed to avoid cost blow outs and a fragmented primary care network under review recommendations

Media Release 7 November 2024 The Primary Care Business Council (PCBC) has warned a cautious approach is needed in responding to the recommendations of the Scope of Practice report which could put Australia’s primary care network at risk of becoming more costly and fragmented. PCBC Chair Dr Ged Foley said there could be serious consequences to implementing the Scope of Practice report recommendations in full. “GPs will rightly be concerned that the findings of this report put into practice will lead us down a path to a fragmented primary care system that will be costlier for all,” Dr Foley said.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans